Drug intelligence / Profile preview

Tripamide

Development stage: Unknown
Lead developer: Sterling Winthrop
Modality: Small Molecules
Administration: Oral

Overview

Tripamide is a sulfonamide-derived diuretic and antihypertensive agent. It is widely used in clinical practice for the treatment of hypertension and edema. Its mechanism of action involves inhibiting solute reabsorption in the thick ascending limb of Henle's loop, leading to increased diuresis. Additionally, it exerts antihypertensive effects by reducing total peripheral vascular resistance, decreasing cardiac output at higher doses, and inhibiting central sympathetic vasomotor activity. It also demonstrates vasodilation properties by suppressing contractions in vascular smooth muscles.

Targets

NKCC2 (Sodium-potassium-chloride cotransporter 2)

Beyond the preview

Go deeper on Tripamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tripamide.

Explore the full profile